NBI-921352
NBI-921352-FOS2021
Phase 2 small_molecule completed
Quick answer
NBI-921352 for Focal Onset Seizure is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 2 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Focal Onset Seizure
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed